FDG-PET

Caron Treatment Centers Expands Its Neurorestorative Health Care Services

Retrieved on: 
Thursday, February 8, 2024

Caron Treatment Centers , a nonprofit behavioral healthcare leader for almost 70 years dedicated to treatment, research, prevention and addiction medical education, announces the expansion of its groundbreaking Neurorestorative Health Care services provided at The Keele Medical Center in Delray Beach, Fl.

Key Points: 
  • Caron Treatment Centers , a nonprofit behavioral healthcare leader for almost 70 years dedicated to treatment, research, prevention and addiction medical education, announces the expansion of its groundbreaking Neurorestorative Health Care services provided at The Keele Medical Center in Delray Beach, Fl.
  • “We’re excited to share this expertise more broadly and expand our Neurorestorative Health Care offerings to help more individuals optimize their brain health.”
    Individuals interested in more information about Caron’s 10-day Neurocognitive Assessment or its Neurorestorative Health Care can visit caron.org/neuro-assessment or call 877-369-0109.
  • Caron Treatment Centers is an internationally recognized nonprofit dedicated to addiction and behavioral healthcare treatment, research, prevention, and addiction medicine education.
  • Caron also provides concierge signature treatment for executives, healthcare professionals and older adults and offers Neurorestorative Health Care at our Keele Medical Center in Palm Beach County, Fl.

Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule

Retrieved on: 
Monday, December 4, 2023

ROCHESTER, N.Y., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease and cancer, previously reported that on October 10, 2023 it was advised by Nasdaq that the Company was no longer in compliance with Nasdaq’s minimum bid price requirement and that Nasdaq could move to suspend trading of the common stock and to delist the Company’s securities unless the company appealed Nasdaq’s determination. The Company appealed that decision and has been granted an exception until March 4, 2024 to address this issue. Subject to fulfilling its commitments to Nasdaq, it is expected that Vaccinex shares will continue to be listed on the Nasdaq Capital Market throughout this time and subsequently if compliance is restored.

Key Points: 
  • The Company appealed that decision and has been granted an exception until March 4, 2024 to address this issue.
  • Subject to fulfilling its commitments to Nasdaq, it is expected that Vaccinex shares will continue to be listed on the Nasdaq Capital Market throughout this time and subsequently if compliance is restored.
  • The last patient in this trial is expected to complete the planned 12-months of treatment by early June 2024.
  • We believe that these findings portend a potentially favorable clinical outcome for pepinemab treatment in AD.

Machine learnings has potential to assist with diagnosis in Parkinsonian syndromes

Retrieved on: 
Sunday, August 27, 2023

COPENHAGEN, Denmark, Aug. 27, 2023 /PRNewswire-PRWeb/ -- Parkinsonian syndromes diagnosis was assisted by machine learning reliably in an international study released today at the International Congress of Parkinson's Disease and Movement Disorders® in Copenhagen, Denmark.

Key Points: 
  • Parkinsonian syndromes diagnosis was assisted by machine learning reliably in an international study released today at the International Congress of Parkinson's Disease and Movement Disorders® in Copenhagen, Denmark.
  • COPENHAGEN, Denmark, Aug. 27, 2023 /PRNewswire-PRWeb/ -- Parkinsonian syndromes diagnosis was assisted by machine learning reliably in an international study released today at the International Congress of Parkinson's Disease and Movement Disorders® in Copenhagen, Denmark.
  • Parkinsonian syndromes — multiple systems atrophy and progressive supranuclear palsy — present with similar clinical symptoms as Parkinson's disease but are distinct diseases with available corresponding therapies.
  • In this study, PET scans were leveraged to train a machine learning algorithm to differentiate the scans of patients with varying Parkinsonian syndromes.

Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association

Retrieved on: 
Thursday, May 11, 2023

HEIDELBERG, Germany, May 11, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that two abstracts have been accepted to EHA2023, the annual meeting of the European Hematology Association (EHA) taking place in Frankfurt, Germany on June 8-11, 2023.

Key Points: 
  • HEIDELBERG, Germany, May 11, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that two abstracts have been accepted to EHA2023, the annual meeting of the European Hematology Association (EHA) taking place in Frankfurt, Germany on June 8-11, 2023.
  • In the REDIRECT study, the AFM13 innate cell engager (ICE®) exhibited clinical efficacy in a heavily pre-treated CD30-positive r/r PTCL population.
  • Overall, the objective response rate (ORR) based on FDG-PET assessed by an independent review committee was 32.4%, thus comparable to therapies approved for this indication.
  • The median duration of response, progression-free survival, and overall survival were 2.3, 3.5, and 13.8 months, respectively.

Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting

Retrieved on: 
Saturday, December 10, 2022

Results from the study continue to demonstrate high objective and complete response rates with a well-tolerated safety profile.

Key Points: 
  • Results from the study continue to demonstrate high objective and complete response rates with a well-tolerated safety profile.
  • Across all 35 patients treated at the RP2D, a 94% ORR and a CR rate of 71% were observed.
  • “It’s impressive that we continue to see these response rates in a patient population that has exhausted all other treatment options.
  • Session: Cellular Immunotherapies: Early Phase and Investigational Therapies: Lymphoma
    Affimed will host an investor event to review AFM13 clinical data and development plans in CD30-expressing malignancies.

Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

Retrieved on: 
Saturday, December 10, 2022

The safety profile of AFM13 was well managed and consistent with previously reported data of prior and ongoing clinical studies with AFM13.

Key Points: 
  • The safety profile of AFM13 was well managed and consistent with previously reported data of prior and ongoing clinical studies with AFM13.
  • “Our parallel study investigating AFM13 in combination with allogeneic NK cells shows that this combination can materially improve clinical outcomes for patients with CD30-postive lymphomas.
  • Secondary and exploratory outcome measures included DoR, PFS, OS, the safety of AFM13 as well as pharmacokinetics and immunogenicity of AFM13.
  • AFM13 is Affimed’s most advanced ICE® clinical program and is currently being evaluated as monotherapy in a registration-directed trial in patients with relapsed/refractory peripheral T-cell lymphoma (REDIRECT).

New Study in JNCCN Suggests Way to Predict Outcomes with High Accuracy Prior to Surgery for Pancreatic Cancer Patients

Retrieved on: 
Thursday, September 8, 2022

PLYMOUTH MEETING, Pa., Sept. 8, 2022 /PRNewswire/ -- New research in the September 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds the use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant prognostic benefit in objectively assessing neoadjuvant chemotherapy response in borderline resectable/locally advanced pancreatic cancer patients prior to surgery.

Key Points: 
  • "We were astonished by how metabolic imaging can now predict outcomes with high accuracy before any surgical intervention," said senior research Mark J. Truty, MD, MS, Mayo Clinic Comprehensive Cancer Center.
  • According to previous studies, traditional imaging modalities such as CT and/or MRI are ineffective at predicting outcomes from the pre-surgery treatment of neoadjuvant chemotherapy in pancreatic cancer patients.
  • The study included 202 patients with borderline resectable/locally advanced pancreatic cancer who received either mFOLFIRINOX or gemcitabine/nab-paclitaxel as first-line neoadjuvant chemotherapy.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

New Study in JNCCN Suggests Way to Predict Outcomes with High Accuracy Prior to Surgery for Pancreatic Cancer Patients

Retrieved on: 
Thursday, September 8, 2022

PLYMOUTH MEETING, Pa. , Sept. 8, 2022 /PRNewswire/ -- New research in the September 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds the use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant prognostic benefit in objectively assessing neoadjuvant chemotherapy response in borderline resectable/locally advanced pancreatic cancer patients prior to surgery.

Key Points: 
  • "We were astonished by how metabolic imaging can now predict outcomes with high accuracy before any surgical intervention," said senior research Mark J. Truty, MD, MS, Mayo Clinic Comprehensive Cancer Center.
  • According to previous studies, traditional imaging modalities such as CT and/or MRI are ineffective at predicting outcomes from the pre-surgery treatment of neoadjuvant chemotherapy in pancreatic cancer patients.
  • The study included 202 patients with borderline resectable/locally advanced pancreatic cancer who received either mFOLFIRINOX or gemcitabine/nab-paclitaxel as first-line neoadjuvant chemotherapy.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation

Retrieved on: 
Monday, August 8, 2022

ROCHESTER, N.Y., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), today announced that results of its Phase 2 SIGNAL study to evaluate its SEMA4D-blocking antibody, pepinemab, in patients with Huntington’s Disease (HD) were published in the August 8, 2022 issue of Nature Medicine1, a leading journal for publication of translational and clinical research. In parallel, a second report has been published in the Journal of Neuroinflammation2 detailing the pathologic impact of SEMA4D on neuroinflammatory cells in both HD and Alzheimer’s disease (AD).

Key Points: 
  • These findings encourage continued development of pepinemab as a potential therapy for patients with early manifest symptoms of HD and potentially AD.
  • Accordingly, a phase 1b/2a study of pepinemab in Alzheimers disease has been initiated and is actively enrolling patients (NCT04381468).
  • The mechanism of action of pepinemab, targeting neuroinflammation2, may provide an alternative to other AD therapies that target aggregates of A amyloid.
  • The Nature Medicine publication is available online at https://www.nature.com/articles/s41591-022-01919-8 and Journal of Neuroinflammation at https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-022... ; both articles will also be posted on the Vaccinex website.

Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting

Retrieved on: 
Sunday, April 10, 2022

Still the combination of AFM13 and precomplexed NK cells resulted in a 100% response rate and a 62% rate of complete responses.

Key Points: 
  • Still the combination of AFM13 and precomplexed NK cells resulted in a 100% response rate and a 62% rate of complete responses.
  • There were six infusion-related reactions in 110 infusions (5.4%) of AFM13 alone and no reactions to the cord blood-derived NK cells precomplexed with AFM13.
  • When precomplexed with AFM13, NK cells exhibit immediate expansion in the patients circulation which persists for at least two weeks.
  • The study is a dose-escalation trial of pre-complexed NK cells, with patients receiving 1106 NK cells/kg in Cohort 1; 1107 NK cells/kg in Cohort 2; and 1108 NK cells/kg in Cohort 3.